• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
CONCLUSION: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.PRIMARY FUNDING SOURCE: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.PMID:37155984 | DOI:10.7326/M22-2751
Source: Annals of Internal Medicine - May 8, 2023 Category: Internal Medicine Authors: Tadarro L Richardson Alese E Halvorson Amber J Hackstadt Adriana M Hung Robert Greevy Carlos G Grijalva Tom A Elasy Christianne L Roumie Source Type: research

Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research

First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
CONCLUSION: As first-line agents, SGLT2 inhibitors and GLP1 receptor agonists would improve type 2 diabetes outcomes, but their costs would need to fall by at least 70% to be cost-effective.PRIMARY FUNDING SOURCE: American Diabetes Association.PMID:36191315 | DOI:10.7326/M21-2941
Source: Annals of Internal Medicine - October 3, 2022 Category: Internal Medicine Authors: Jin G Choi Aaron N Winn M Reza Skandari Melissa I Franco Erin M Staab Jason Alexander Wen Wan Mengqi Zhu Elbert S Huang Louis Philipson Neda Laiteerapong Source Type: research

People With Diabetes Are More Vulnerable to Heart Disease. How to Reduce the Risk
If you’ve been diagnosed with diabetes, know that you’ve got plenty of company. The American Diabetes Association (ADA) reports that in 2019, the most recent year for which data is available, 37.3 million adults in the U.S.—about 11.3% of the population—had the chronic condition, and that number continues to grow. Type 1 diabetes develops when the body isn’t able to produce insulin, and Type 2 occurs when the body doesn’t use insulin correctly. Type 2 is the most common form of diabetes, and when it’s uncontrolled, a person’s blood sugar can jump to dangerous levels that requ...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Elaine K. Howley Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research

Pages: 1  2  3